Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMUXNASDAQ:MITONASDAQ:XBITNASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMUXImmunic$0.92-0.3%$1.04$0.83▼$2.11$87.92M1.73719,429 shs445,534 shsMITOStealth BioTherapeutics$0.32$0.32$0.16▼$1.03$23.54M1.46946,105 shsN/AXBITXBiotech$2.84$3.05$2.65▼$8.64$86.59M0.9875,687 shs39,527 shsZNTLZentalis Pharmaceuticals$1.20-3.2%$1.38$1.01▼$13.00$86.34M1.811.55 million shs778,244 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMUXImmunic-0.34%-4.52%-16.58%-27.06%-27.75%MITOStealth BioTherapeutics0.00%0.00%0.00%0.00%0.00%XBITXBiotech0.00%-6.58%-10.13%-5.02%-66.94%ZNTLZentalis Pharmaceuticals-3.23%-4.76%-20.00%-48.28%-89.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMUXImmunic2.3707 of 5 stars3.63.00.00.02.50.80.6MITOStealth BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AXBITXBiotech0.5043 of 5 stars0.01.00.00.02.02.50.6ZNTLZentalis Pharmaceuticals1.7767 of 5 stars3.21.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMUXImmunic 3.25Buy$13.001,316.74% UpsideMITOStealth BioTherapeutics 0.00N/AN/AN/AXBITXBiotech 0.00N/AN/AN/AZNTLZentalis Pharmaceuticals 2.44Hold$8.24587.04% UpsideCurrent Analyst Ratings BreakdownLatest MITO, XBIT, IMUX, and ZNTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/15/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.005/15/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/1/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/28/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMUXImmunicN/AN/AN/AN/A$0.64 per shareN/AMITOStealth BioTherapeutics$21.09M1.12N/AN/A($0.79) per share-0.41XBITXBiotech$4.01M21.59N/AN/A$7.19 per share0.39ZNTLZentalis Pharmaceuticals$26.87M3.21N/AN/A$6.18 per share0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%N/AMITOStealth BioTherapeutics-$52.53M-$0.52N/AN/AN/AN/AN/A-142.81%N/AXBITXBiotech-$24.56M-$1.29N/A∞N/AN/A-15.99%-14.85%8/11/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$292.19M-$3.13N/AN/AN/AN/A-43.91%-34.96%8/8/2025 (Estimated)Latest MITO, XBIT, IMUX, and ZNTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/14/2025Q1 2025XBITXBiotechN/A-$0.36N/A-$0.36N/AN/A5/14/2025Q1 2025ZNTLZentalis Pharmaceuticals-$0.67-$0.67N/A-$0.67N/AN/A3/26/2025Q4 2024ZNTLZentalis Pharmaceuticals-$0.75-$0.66+$0.09-$0.66N/A$26.90 million3/18/2025Q4 2024XBITXBiotechN/A-$0.34N/A-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMUXImmunicN/AN/AN/AN/AN/AMITOStealth BioTherapeuticsN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMUXImmunicN/A2.712.71MITOStealth BioTherapeuticsN/A3.683.68XBITXBiotechN/A11.5711.57ZNTLZentalis PharmaceuticalsN/A7.297.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMUXImmunic51.82%MITOStealth BioTherapeutics2.21%XBITXBiotech55.70%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipIMUXImmunic3.00%MITOStealth BioTherapeuticsN/AXBITXBiotech33.10%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMUXImmunic7095.82 million87.38 millionOptionableMITOStealth BioTherapeutics2973.55 millionN/ANot OptionableXBITXBiotech10030.49 million20.39 millionOptionableZNTLZentalis Pharmaceuticals16071.95 million68.70 millionOptionableMITO, XBIT, IMUX, and ZNTL HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Takes $703,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 20, 2025 | marketbeat.comHC Wainwright Brokers Raise Earnings Estimates for ZNTLMay 20, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for ZNTL EarningsMay 20, 2025 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Neutral Rating from WedbushMay 18, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)May 17, 2025 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comZentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational ProgressMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Makes New Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 14, 2025 | marketbeat.comAlmitas Capital LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Makes New $1.36 Million Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)May 4, 2025 | marketbeat.comFirst Patient Dosed With Azenosertib in Cyclin E1+ Ovarian CancerMay 3, 2025 | curetoday.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comZentalis Pharmaceuticals (ZNTL) to Release Earnings on TuesdayMay 1, 2025 | marketbeat.comScott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) StockMay 1, 2025 | insidertrades.comZentalis shares insights on cancer research at AACRApril 29, 2025 | investing.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by BrokeragesApril 29, 2025 | marketbeat.comZentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROCApril 28, 2025 | globenewswire.comDecheng Capital LLC Trims Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)April 28, 2025 | marketbeat.comWalleye Capital LLC Makes New $587,000 Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)April 25, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)April 25, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMITO, XBIT, IMUX, and ZNTL Company DescriptionsImmunic NASDAQ:IMUX$0.92 0.00 (-0.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.93 +0.01 (+1.24%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Stealth BioTherapeutics NASDAQ:MITOStealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.XBiotech NASDAQ:XBIT$2.84 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.86 +0.02 (+0.53%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.20 -0.04 (-3.23%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.58%) As of 05/23/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
